Φάσσας

ΕΡΕΥΝΑ ΚΑΙ ΔΗΜΟΣΙΕΥΣΕΙΣ

1. Barlogie, B., Tricot, G, Anaissie, E, Shaughnessy, J, Rasmussen, E, van Rhee F, Fassas, A, Zangari, M, Hollmig, K, Pineda-Roman M, Lee, C, Talamo, G, Thertulien R, Kiwan, E, Krishna S, Fox M and Crowley J.  Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. In New England Journal of Medicine 10: 1021–1030 , 2006
2. Fassas A B-T, Spencer T, Sawyer J, Zangari M, Lee C-K, Anaissie E, Morris C, Barlogie B, and Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. British Journal of Haematology. 
3. Fassas A B-T, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, and Tricot G. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients.British Journal of Haematology. 
4. Fassas ABT, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, MathewS, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. British Journal of Haematology 117:103-108, 2002. 
5. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, AnaissieE, Van Rhee F, Tricot G. Improved outcome of non-myeloablative allogeneic transplantation in multiple myeloma. Journal of Clinical Oncology 20:1295-1303, 2002. 
6. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Heman M, Badros A, Kennedy A, Jacobs M, Judes R, Ruehle K, Smith R, Kight L, Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G. Autotransplantation for advanced lymphoma and Hodgkin disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplantation 29:303-312, 2002. 
7. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. BloodCoagulation and Fibronolysis 13:131-136, 2002. 
8. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, YangY, WilsonC, Zangari M, Anaissie E, Morris C, Muwalla F, Van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessey J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrowplasma cells. Blood 99:1745-1757, 2002. 
9. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. Predicting long-term (≥ 5 years) event-freesurvival in multiple myeloma patients following planned tandem autotransplants. British Journal of Haematology 116:211-217, 2002. 
10.  Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. British Journal of Haematology 114:822-829, 2001. 
11.  Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, Tricot G. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. British Journal of Haematology 114:600- 607, 2001. 
12.  Fassas AB-T, Rapoport AP, Bolaños-Meade J, Shanholtz C, Cottler-Fox M, Tricot G. Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leukemia and Lymphoma 42:1323-1328, 2001. 
13.  Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Toor A, Cottler-Fox M, Fassas A, Anaissie EJ, Schichman S, Tricot G. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97:2574-2579, 2001. 
14.  Fassas A, Gojo I, Rapoport A, Cottler-Fox M, Meisenberg B, Papadimitriou JC, Tricot G. Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy. Bone Marrow Transplantation 28:399-403, 2001. 
15.  Fassas A, Buddharaju LN, Rapoport A, Cottler-Fox M, Drachenberg C, Meisenberg B, Tricot G. Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation. Leukemia and Lymphoma 42:535-542, 2001. 
16.  Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B. Preceding chemotherapy, tumor load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. British Journal of Haematology 112:242-247, 2001. 
17.  Fassas A, Bolanos-Meade J, Buddharaju LN, Rapoport A, Cottler-Fox M, Chen T, Lovchik JC, Cross A, Tricot G. Cytomegalovirus infection causes non-neutropenic fever after autologous stem cell transplantation. British Journal of Haematology 112:237- 241, 2001. 
18.  Fassas AB-T, Rapoport AP, Cottler-Fox M, Chen T, Tricot G. Encouraging preliminary results in 12 patients with high-risk haematologic malignancies by omitting Graft- versus-Host disease prophylaxis after allogeneic transplantation. British Journal of Haematology 111: 662-667, 2000. 
19.  Desikan KR, Tricot G, Dhodopkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Mehta J, Spoon D, Anaissie E, Barlogie B, Munshi N. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplantation 25:483-487, 2000. 
20.  Aslan T, Fassas AB-T, Desikan R, Siegel D, Munshi NC, Mehta J, Singhal S, Barlogie B, Anaissie E. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone MarrowTransplantation 24:505-509, 1999. 

‍